Phase 3 Trials at Kidney Week 2026 Show New Promise for IgA Nephropathy Care
Phase 3 trial results presented at ASN Kidney Week 2026 show that atacicept, sibeprenlimab and telitacicept provided kidney protection for ...
Tag: APRIL
New Kidney Disease Therapies Strike at the Root of IgA Nephropathy
A new review maps how mechanism-based therapies targeting galactose-deficient IgA1 are transforming IgA nephropathy treatment, from mucosal interventions to APRIL ...
Scientists Use Immune Informatics to Sketch a First Vaccine Blueprint Against Human Metapneumovirus
A computational reverse vaccinology study has designed BAFF- and APRIL-adjuvanted multi-epitope vaccine candidates against human metapneumovirus, a major respiratory pathogen ...
Fast-Acting Drug Pair Pulls Patient Back From Brink of Myasthenic Crisis
Doctors in China report the first sequential use of efgartigimod and telitacicept to rescue a 73-year-old MuSK-myasthenia gravis patient from ...
Lab-Grown B Cells Reveal Why Immune Defenses Falter in Common Variable Immunodeficiency
Researchers in Madrid have developed an in vitro stimulation model showing that B cells from patients with common variable immunodeficiency ...
-
Mothers who receive childcare support from maternal grandparents show more parental warmth, finds NTU Singapore study
-
University of Seville Breaks 120-Year-Old Mystery, Revises a Key Einstein Concept
-
Bee body mass, pathogens and local climate influence heat tolerance
-
Researchers record first-ever images and data of a shark experiencing a boat strike
-
Groundbreaking Clinical Trial Reveals Lubiprostone Enhances Kidney Function
Embark on a thrilling journey of discovery with Scienmag.com—your ultimate source for cutting-edge breakthroughs. Immerse yourself in a world where curiosity knows no limits and tomorrow’s possibilities become today’s reality!